TEL AVIV, Israel, June 29, 2010 BSP, whichdevelops and commercializes advanced products for the non invasive, accuratediagnosis of heart diseases, announced today that its Add-On product, theHyperQ AD-100 (http://www.bsp.co.il/pdf/HyperQ%20AD-100%20Pic.pdf), intendedfor improved diagnostic performance of Stress ECG, has been granted theEuropean CE conformance mark. The HyperQ AD-100 product is an add-on systemwith the HyperQ technology which is incorporated in parallel to existingstandard stress ECG systems. The integration of the HyperQ AD-100 into StressECG systems enables accurate and sensitive diagnosis of Ischemic HeartDisease, a leading cause of death in the world.
The unique technology developed by BSP is implemented in a non invasivemanner and does not involve exposure to radiation or other hazards topatients. It is highly effective in diagnosing sick people and in ruling outdisease in healthy individuals. The HyperQ AD-100 enables physicians tobenefit from the clinical advantages of the technology without the need toreplace their existing installed Stress ECG system.
BSP CEO, Nissim Greisas: "The integration of the HyperQ Add-On systemsinto the vast installed base of standard Stress ECG systems significantlyexpands our potential global market. The worldwide annual stress ECG systemmarket is estimated at $200M, and the total standard ECG installed baserepresents an estimated $800M market for the new product."
CE mark was also granted to BSP's software product - the HyperQ-AN. Thisproduct enables analysis with the unique HyperQ technology and can beemployed in OEM and licensing business models in existing commercial stressECG systems, such as the company's collaboration with Schiller AG.
Founded in 2000, BSP is dedicated to providing novel, risk free andhighly reliable solutions for the diagnosis and monitoring of cardiovasculardisease. BSP's proprietary HyperQ(TM) technology is implemented in cardiacsystems that offer accurate, low-cost and risk free cardiac monitoring andallows, for the first time, an effective diagnosis of ischemic heart diseasein broad populations. BSP is a traded company on the Tel Aviv Stock Exchangesince 2006 (TASE:BSP). The company's international offices are located in TelAviv, Israel and Rockville, Maryland, USA.For more information please contact: Nissim Greisas, CEO, Biological Signal Processing Ltd. email@example.com Tel. +972-3-6474840
SOURCE BSP - Biological Signal Processing Ltd